Everest Organics Limited have received the initial order for supply of Omiprazole API to US Market.
The company has tie-up with an US based Pharma Company and the same has resulted in the first trial order for the company. This is significant development in history of the company after the successful completion of USFDA audit.
Commenting on the important development, Dr. Sri Kakarlapudi Srihari Raju, Manging Director, Everest Organics Ltd.,(Everest) said, "We see excellent opportunity to drive increased sales and profitability by growing our sales to regulated market over the period of two to three years." "Today's transaction marks the start of a new chapter as part of the Everest Organization, as well as the opportunity to participate in the significant upside potential of the company. The entry into the US market is a significant step forward in strengthening our presence in developed market."
Shares of EVEREST ORGANICS LTD. was last trading in BSE at Rs.151.2 as compared to the previous close of Rs. 159.15. The total number of shares traded during the day was 7695 in over 120 trades.
The stock hit an intraday high of Rs. 163.65 and intraday low of 151.2. The net turnover during the day was Rs. 1190073.